Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 19, 2026
Reporting Period: Single event date (February 19, 2026)
This filing reports a corporate event under Item 8.01 (Other Events). The Company announced it will host a webinar on February 26, 2026, regarding CORDStrom, a therapy for the treatment of recessive dystrophic epidermolysis bullosa.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document solely announces an upcoming corporate communication event.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Webinar scheduled for February 26, 2026, at 1:00 p.m. ET.
- Subject Matter: CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa.
- Reference: A press release detailing the event is attached as Exhibit 99.1.
The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard disclosure of the event.
Investor Verification Checklist
- Verify the date and time of the upcoming webinar (February 26, 2026, 1:00 p.m. ET).
- Review the attached press release (Exhibit 99.1) for detailed information on CORDStrom.
- Confirm the Company's status as an emerging growth company (indicated as not applicable in this filing).